The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Blockbuster or maybe just more updates. Either would keep people interested and show holders that progress is being made.
This can barely hold £1, let alone £2 or £4. Someone is adamant on selling at every opportunity, which is annoying. We need some blockbuster news for this as I see gdr as one of those companies which nothing but “out of this world” news would make a difference. Anything else and this will be sold down by those having suffered for months here. On the other hand, you have ncyt and avct which even if they release “the Director has had a fart”, the SP goes up. Ridiculous!
Yup roll on £4 let alone £2.
Cheers and have a good weekend
I agree Groover we should be sitting past £2 already... Seems like the market wants more confirmation on approvals & sales numbers before any serious re rate.. Won't be to long now and with the Virus back with avenengance and taking a seemingly stronger grip than before Covid players are back in the limelight for the foreseeable future... Plenty upside from here that's for sure.
BBench hope so mate because this current SP is staggering. How did we get to this low level again! Ridiculous given potential here and positive RNS the other day
GLA
Plenty news on many fronts to come here over next few weeks...once £2 is broken it's upwards to god knows where.
Well if US Corp legal involved....maybe so!
Apologies - acknowledge they are progressing swab, what I meant is I hope they go full steam on that aspect to get scores on the doors (to the detriment maybe of saliva)....ideally they have capacity to progress both.
.....but one in the hand is worth 2 in the bush and all that...;0)
plus we all seam to be ignoring that they going ahead with other swabs first
the delay was Beckmans legal department if i read it right and a two week delay from them is not a surprise in U.S. tbh
.....oh, and if they do land mass automated saliva, that’s clearly huge. Even if it takes 6 weeks from now - demand will still be here.
Love it ;0)
I think we all felt a tad deflated yesterday, but actually there’s been no ‘failure’ to report yet on any fronts - eg approvals rejected / collab not viable etc, and we’re still circa 30% higher than 2 weeks ago.
II Seller not helping, but maybe that’s always in play in AIM, but do see an easing on the sell front coming over next few weeks.
Buckle in, BudExpres on another rocky detour but destination remains the same....
#PlantPower
Yea, PP, RNS was not clear on a few points, “they” who are they? Etc
Anyway, fingers crossed going forward.
Peace Plant Poirot
I agree that the two weeks thing is unlikely, I’d go for a 30minute quick scan and send.
PP yes, that also makes sense, crack on get part 1 done while we are still working on part 2, saliva, hope it falls into place.
I think who will be first approval, think I have said that since day one but would be happy to be wrong! I have a bet with someone from early on, I can’t remember who it was, they said FDA first.
@Dave 77 - not sure if below is also the evaluation lab referenced in Aug RNS, expect one off the same, eg evaluate at clinical lab you’re going to use:
“...with initial introduction in the USA at an already identified clinical laboratory”
Regarding if reg approvals required or not - below stated in yesterday’s RNS, so infers maybe they are required but is this inclusive of saliva and swab - or just saliva:
“ We will obtain regulatory approvals prior to a final solution release."
Lots of questions - bring out Poirot & Elizabeth Fletcher..
Good point Invest4theLT that if 2 weeks was ‘true’ then you would expect they are further down the line now.
I know timescales has caused ‘pressure’ and can see why this may be avoided going forwards, but if for swabs there is no reg dependencies and solely in GDR / BC’s hands I would expect some timescales for investors to digest even if element of sandbagging built in.
The 2 week reference seems slightly unbelievable in my eyes - would they really take 2 weeks finessing language for an RNS (that’s not great if so).
I personally believe (I know to the contrary of company PR..) that DB’s hand was forced....I mentioned yesterday that I posted a link to the updated instructions which referenced BC kit validation that MOILY highlighted on twitter, I think that might have been trigger and maybe plan was to wait a few weeks...who knows, I’ll leave it there.
My concern is BC saliva could drag on, as clearly difficult for good reason, so mentioned before I hope the progress swab automation and get machines evaluated / validated and crack on with initial production sales with saliva being the cherry on cake to take this to the next level.
I expect evaluation lab can self certify test without FDA approval, so hopefully no external dependencies (other than BC), but may be wrong.
I feel per previous post India is close and really needs to land to take pressure off above or if not can see us sliding back (if only for 2-4 weeks) prior to BC further news / FDA / WHO approval. There is also the year end / annual update due, which is maybe what DB was waiting for, but again, not expecting anything material.
So feel we need India - or more short term pain.
Long term still confident, but I too am getting a bit impatient.
PP
There are positives in the rns Dave77 but people wanted more. These things clearly take time though. I too would like regular updates showing progress. We’re left waiting too long without any news. For example, maybe they could let us know when the lab is set up and e2e validation underway. Having said that, there was a post yesterday morning saying it took two weeks to get the wording agreed, so by the time we hear they’ll probably be even further down the line.
The main positive here is BC are still working with us.
Grim, hope your right. I felt that Genedrive had to get the Chemistry between the 2 companies offerings right and BC the machine part.
worth noting that gaining a viable saliva sample is Beckman's problem we just test the sample provided by there tech.
if i have understood right.
After another review of the rns, is below not a fair summery.
We have the same specimen accuracy using Biomek 7 as our prev test on the bead. We can now use our test on several PCR devices that labs will have in situ.
We have been working on the saliva test but so far we are not meeting FDA levels for accuracy , we need further unspecified time to resolve this. Although we think we should manage it.
Evaluation site (is this lab mentioned in Aug) as being set up and we will test on swab tests first then moving onto saliva if we manage to get clinical accuracy higher.
I’m guessing the FDA will evaluate soon after more validating internally on both at the evaluation centre.
My thoughts.
So we need a evaluation lab to be set up and FDA to approve both or at least one method. I understand putting a time limit on the last rns May have put GDR under pressure, so no time given. It would be better going forward, an RNS, evaluation set up complete and evaluation process started , or evaluation set up and evaluation complete, waiting on external approval which should be done by.... Updates on a more regular basis as tbh I thought the bead was already compatible with most PCR machines as prev mentioned I think on the presentation in the summer. I hope next week is a better week. I’m all up for supporting the company and David Budd but I am starting to feel like a mushroom! Technic do you feel above is about right or do you have an objective take of the RNS. Happy to be slated and given another view.